Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) to an Overweight ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached the initial release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...